Therapeutic drug monitoring—Does it really matter?
British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1527-1529
DOI: 10.1111/bcp.16387 ↗Kurz gefasst
Editorial in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.12.2024. Verfasst von Hans Lennernäs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Bioscience, Drug Discovery and Development, Uppsala University, Uppsala, Sweden. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Pharmaceutical Bioscience, Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
- A2-Ai LLC, Ann Arbor, Michigan, USA.
- Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
ORCID-Profile: Hans Lennernäs, Dennis A Hesselink
Förderung
- HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
Zitieren
APA
Lennernäs, H., Cook, J., & Hesselink, D. A. (2025). Therapeutic drug monitoring—Does it really matter?. British Journal of Clinical Pharmacology, 91(6), 1527-1529. https://doi.org/10.1111/bcp.16387
Vancouver
Lennernäs H, Cook J, Hesselink DA. Therapeutic drug monitoring—Does it really matter?. British Journal of Clinical Pharmacology. 2025;91(6):1527-1529. doi:10.1111/bcp.16387
BibTeX
@article{Lennerns2025,
author = {Lennernäs, Hans and Cook, Jack and Hesselink, Dennis A},
title = {Therapeutic drug monitoring—Does it really matter?},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {6},
pages = {1527--1529},
doi = {10.1111/bcp.16387}
}
EUVIMED